Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L. George G, et al. Among authors: guru murthy gs. Leuk Res. 2020 Jul;94:106368. doi: 10.1016/j.leukres.2020.106368. Epub 2020 May 11. Leuk Res. 2020. PMID: 32442786 Clinical Trial. No abstract available.
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Kanate AS, et al. Among authors: guru murthy gs. Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302. doi: 10.1016/j.bbmt.2017.04.009. Epub 2017 Apr 12. Biol Blood Marrow Transplant. 2017. PMID: 28412518 Free article. Clinical Trial.
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Guru Murthy GS, et al. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833. doi: 10.1016/j.bbmt.2018.12.069. Epub 2018 Dec 18. Biol Blood Marrow Transplant. 2019. PMID: 30572109 Free article.
Treatment-Free Remission in CML: the US Perspective.
Guru Murthy GS, Atallah E. Guru Murthy GS, et al. Curr Hematol Malig Rep. 2019 Feb;14(1):56-61. doi: 10.1007/s11899-019-0496-8. Curr Hematol Malig Rep. 2019. PMID: 30645715 Review.
Myeloid malignancies after treatment for solid tumours.
Guru Murthy GS, Abedin S. Guru Murthy GS, et al. Best Pract Res Clin Haematol. 2019 Mar;32(1):40-46. doi: 10.1016/j.beha.2019.02.012. Epub 2019 Feb 26. Best Pract Res Clin Haematol. 2019. PMID: 30927974 Review.
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.
Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS. Mushtaq MU, et al. Among authors: guru murthy gs. Leuk Lymphoma. 2021 Jan;62(1):158-166. doi: 10.1080/10428194.2020.1821009. Epub 2020 Sep 19. Leuk Lymphoma. 2021. PMID: 32951486
40 results